Home
Products & Services
Support
About
Contact Us
FinancialContent is the trusted provider of stock market information to the media industry.
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Biogen Idec (NQ: BIIB)
302.86 USD  +1.41 (+0.47%)
Official Closing Price  /  Updated: 7:51 PM EDT, Jun 2, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 946,000
Open 300.28
Bid (Size) 300.76 (1)
Ask (Size) 303.35 (4)
Prev. Close 301.45
Today's Range 300.28 - 303.92
52wk Range 215.77 - 374.99
Shares Outstanding 211,007,945
Dividend Yield N/A
Performance
YTD
+2.93%
+2.93%
1 Month
+2.14%
+2.14%
3 Month
-4.09%
-4.09%
6 Month
+4.18%
+4.18%
1 Year
+35.59%
+35.59%
Top News
More News
Vir Biotechnology and Biogen Execute Agreement to Manufacture SARS-CoV-2 Antibodies for Potential COVID-19 Treatment
from GlobeNewswire News Releases
Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science
from GlobeNewswire News Releases
More News
Read More
Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science
category STEM , NASDAQ:BIIB , Biogen , and 8 more.
from 3BL Media: Corporate Social Responsibility, Energy and Health News
The Critical Role of Community Health: Bringing Necessary Services to Key Demographics
category Biogen , NASDAQ:BIIB , Health & Healthcare , and 2 more.
from 3BL Media: Corporate Social Responsibility, Energy and Health News
New Data at AAN Showcase Biogen’s Commitment to Advancing Innovation in MS
from GlobeNewswire News Releases
New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients
from GlobeNewswire News Releases
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2020 Financial Results
from GlobeNewswire News Releases
Samsung Bioepis Announces 24-week Interim Results from a Phase 3 Trial of SB11, Proposed Ranibizumab Biosimilar
from Business Wire News Releases
Vir Biotechnology Is Bucking The Biotech COVID-19 Trends, And Stands To Win
category MRK , GILD , Market News , and 5 more.
from Motley Fool
Noteworthy ETF Outflows: IVE, IBM, FIS, BIIB
category ETFs
from ETF Channel
Got $3,000? Here Are 3 Great Biotech Stocks to Buy Right Now
category Market News , AKCA , IONS , and 6 more.
from Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
   
© Copyright FinancialContent Services, Inc.